Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications

被引:23
作者
Espinoza, Francisco [2 ]
Fabre, Sylvie [1 ]
Pers, Yves-Marie [1 ]
机构
[1] CHU Lapeyronie, Clin Immunol & Osteoarticular Dis Therapeut Unit, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier, France
[2] Univ Los Andes, Sch Med, Dept Rheumatol, Santiago, Chile
关键词
disease-modifying antirheumatic drugs; early rheumatoid arthritis; predictive factors; remission; rheumatoid arthritis; MODIFYING ANTIRHEUMATIC DRUGS; CONTROL TREATMENT STRATEGY; COMBINATION DMARD THERAPY; TREAT-TO-TARGET; DOUBLE-BLIND; RHEUMATOLOGY/EUROPEAN LEAGUE; RADIOGRAPHIC PROGRESSION; EULAR RECOMMENDATIONS; PROGNOSTIC-FACTORS; PLUS METHOTREXATE;
D O I
10.1177/1759720X16654476
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent guidelines on rheumatoid arthritis (RA) point to the importance of achieving remission as soon as possible during the course of the disease. The appropriate use of antirheumatic drugs is critical, particularly in early RA patients, before 24 weeks, since this is a window of opportunity' for treatment to modify disease progression. A treat-to-target strategy added to an aggressive therapeutic approach increases the chance of early remission, particularly in early RA patients. We conducted an overview of current therapeutic strategies leading to remission in early RA patients. We also provide interesting predictive factors that can guide the RA management strategy with regard to disease-modifying treatment and/or drug-free remission.
引用
收藏
页码:107 / 118
页数:12
相关论文
共 61 条
[1]   2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative [J].
Aletaha, Daniel ;
Neogi, Tuhina ;
Silman, Alan J. ;
Funovits, Julia ;
Felson, David T. ;
Bingham, Clifton O., III ;
Birnbaum, Neal S. ;
Burmester, Gerd R. ;
Bykerk, Vivian P. ;
Cohen, Marc D. ;
Combe, Bernard ;
Costenbader, Karen H. ;
Dougados, Maxime ;
Emery, Paul ;
Ferraccioli, Gianfranco ;
Hazes, Johanna M. W. ;
Hobbs, Kathryn ;
Huizinga, Tom W. J. ;
Kavanaugh, Arthur ;
Kay, Jonathan ;
Kvien, Tore K. ;
Laing, Timothy ;
Mease, Philip ;
Menard, Henri A. ;
Moreland, Larry W. ;
Naden, Raymond L. ;
Pincus, Theodore ;
Smolen, Josef S. ;
Stanislawska-Biernat, Ewa ;
Symmons, Deborah ;
Tak, Paul P. ;
Upchurch, Katherine S. ;
Vencovsky, Jiri ;
Wolfe, Frederick ;
Hawker, Gillian .
ARTHRITIS AND RHEUMATISM, 2010, 62 (09) :2569-2581
[2]   Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis [J].
Ally, Mahmood M. T. M. ;
Hodkinson, Bridget ;
Meyer, Pieter W. A. ;
Musenge, Eustasius ;
Tintinger, Gregory R. ;
Tikly, Mohammed ;
Anderson, Ronald .
BMC MUSCULOSKELETAL DISORDERS, 2015, 16
[3]   Understanding the window of opportunity concept in early rheumatoid arthritis [J].
Boers, M .
ARTHRITIS AND RHEUMATISM, 2003, 48 (07) :1771-1774
[4]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[5]   Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort [J].
Choy, Tommy ;
Bykerk, Vivian P. ;
Boire, Gilles ;
Haraoui, Boulos P. ;
Hitchon, Carol ;
Thorne, Carter ;
Keystone, Edward C. ;
Pope, Janet E. .
RHEUMATOLOGY, 2014, 53 (03) :482-490
[6]   EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) [J].
Combe, B. ;
Landewe, R. ;
Lukas, C. ;
Bolosiu, H. D. ;
Breedveld, F. ;
Dougados, M. ;
Emery, P. ;
Ferraccioli, G. ;
Hazes, J. M. W. ;
Klareskog, L. ;
Machold, K. ;
Martin-Mola, E. ;
Nielsen, H. ;
Silman, A. ;
Smolen, J. ;
Yazici, H. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) :34-45
[7]   Two-year clinical and radiologic follow-up of early RA patients treated with initial step up monotherapy or initial step down therapy with glucocorticoids, followed by a tight control approach: lessons from a cohort study in daily practice [J].
De Cock, D. ;
Vanderschueren, G. ;
Meyfroidt, S. ;
Joly, J. ;
Westhovens, R. ;
Verschueren, P. .
CLINICAL RHEUMATOLOGY, 2014, 33 (01) :125-130
[8]   Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial) [J].
Emery, P. ;
Durez, P. ;
Dougados, M. ;
Legerton, C. W. ;
Becker, J-C ;
Vratsanos, G. ;
Genant, H. K. ;
Peterfy, C. ;
Mitra, P. ;
Overfield, S. ;
Qi, K. ;
Westhovens, R. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (03) :510-516
[9]   Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial [J].
Emery, Paul ;
Fleischmann, Roy M. ;
Strusberg, Ingrid ;
Durez, Patrick ;
Nash, Peter ;
Amante, Eric Jason B. ;
Churchill, Melvin ;
Park, Won ;
Pons-Estel, Bernardo ;
Han, Chenglong ;
Gathany, Timothy A. ;
Xu, Stephen ;
Zhou, Yiying ;
Leu, Jocelyn H. ;
Hsia, Elizabeth C. .
ARTHRITIS CARE & RESEARCH, 2016, 68 (06) :744-752
[10]   Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study [J].
Emery, Paul ;
Kvien, Tore K. ;
Combe, Bernard ;
Freundlich, Bruce ;
Robertson, Deborah ;
Ferdousi, Tahmina ;
Bananis, Eustratios ;
Pedersen, Ronald ;
Koenig, Andrew S. .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (06) :989-992